Ponatinib

Researchers detail methods behind bitopic BCR::ABL1 kinase inhibitor study

A methods disclosure describes how researchers sourced and synthesized kinase inhibitors—including ponatinib, asciminib, imatinib, dasatinib and osimertinib—and cultured K562 and HEK293T cell lines to test them. The report details engineered K562 stable lines carrying BCR::ABL1 mutations, created via enzymatic mutagenesis of a pUltra vector, used to evaluate inhibitor activity in cell-based assays.